期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

一线应用靶向药物联合常规化疗治疗晚期非小细胞肺癌的临床观察 被引量：4

下载PDF
导出
摘要 目的评价靶向治疗药物(易瑞沙、特罗凯)联合化疗一线治疗晚期非小细胞肺癌(NSCLC)的临床价值。方法符合入组条件的晚期NSCLC患者38例,除针对患者病情给予常规NP或GP方案化疗外,同时给予易瑞沙,250 mg每日1次,口服,或特罗凯,150 mg每日1次,口服。与35例常规应用化疗药物治疗的晚期NSCLC患者疗效进行对比分析。结果联合用药组35例患者可评价疗效,用药1年余CR 6例(17%),PR 16例(46%),SD 11例(31%),PD 2例(6%),较对照组疗效明显提高,差异有统计学意义,且患者出现皮疹及腹泻等相关副作用可耐受。结论一线应用靶向药物联合常规化疗较单用化疗疗效更好,且副作用可耐受。
作者 张依军 刘刚 王作斌 王强 陈文庆 张洋 苏慧丰
机构地区 吉林省肿瘤医院胸外三科
出处 《中国老年学杂志》 CAS CSCD 北大核心 2009年第12期1531-1532,共2页 Chinese Journal of Gerontology
关键词 非小细胞肺癌 靶向治疗 化学治疗
分类号 R730.2 [医药卫生—肿瘤] R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1Brekken RA ,Thorpe PE. Vascular endothelial growth factor and vascular targetin of solid tumors[ J]. Anticancer Res,2001 ;21 (6B) :4221-49.
  • 2Thatcher N,Chang A,Parikh P,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer( Results from a randomized, placebo-controlled, multicentre study oressa Survival Evaluation in Lung Cancer ) [ J ] . Lancet, 2005 ; 366 ( 9496 ) : 1527-37.
  • 3Shepherd FA, Rodrigues P J, Ciuleanu T, et al. Erlotinib inpreviously treated non-small-cell lung cancer[ J ].N Engl J Med,2005 ;353 (2):123- 32.
  • 4霍伟,冯仲珉,赵卫红,张咏梅,刘晓丹,董华承.吉非替尼治疗晚期非小细胞肺癌64例[J].临床肿瘤学杂志,2005,10(1):4-7. 被引量：23
  • 5潘振奎,张力,张星,王欣,李宁,徐菲,常建华,管忠震.中国非小细胞肺癌患者表皮生长因子受体突变的研究[J].癌症,2005,24(8):919-923. 被引量：44

二级参考文献28

  • 1管忠震,张力,李龙芸,蒋国梁,刘叙仪,储大同,赵洪云,李玮.吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究[J].癌症,2005,24(8):980-984. 被引量：114
  • 2Miller K, Raabe N, Trachtenberg J, et al. ZD1839, an epidermal factor receptor tyrosine kinase inhibitor (EGFR-TKI) ,is well tolerated in combination with mitoxantrone and prednisone in patients with hormone-refactory cancer ( HRPC ) [ J ]. Proc ESMO,2002,91 :abstr 3270.
  • 3Wu YL, Yang XN, Gu LJ. The characteristics of patients with nonsmall cell lung cancer with complete response treated with ZD1839[J]. Proc ASCO ,2003,22:2770a.
  • 4Burris HA 3rd, Moore M J, Andersen J ,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [ J ].Clin Oncol, 1997,15 ( 6 ) : 2403 - 2413.
  • 5Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life- in non-small cell lung cancer : a review of the hterature and future directions[ J]. Clin Cancer Res, 1998,4~1087 - 1100.
  • 6Dy GK, Adjei AA. Novel largets for lung cancer therapy[ M ]. Part 1. J Clin Oncol,2002,20:2881 -2894.
  • 7Barton J,Blackledge G,Wakeling A. Growth factors and their receptors: nee, targets for prostate cancer therapy[J]. Urology,2001,58( 2 Suppl 1) : 114 - 122.
  • 8Fubuoka M, Yano S, Graccone G, et al. Multi-institutional randomized phase Ⅱ trial of Gefitinib for previously treated patients with advanced non-small cell lung cancer[ J ]. Clin Oncolol,2003,21 ( 12 ) : 2237 - 2246.
  • 9Ciardiello F, Caputo R, Bianco R ,et al. Inhibition of growth factor productioll and angiogenesis in human cancer cells by ZD1839 (Iressa) ,a selective epidermal growth factor receptor tyrosine kinase inhibitor[ J ]. Clin Cancer Res,2001,7 ( 5 ) : 1459 - 1465.
  • 10Chan KC, Knox WF, Gandhi A, et al. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation[J]. Br J Surg,2001,88(3) :412 -418.

共引文献60

同被引文献28

  • 1郑直,曲延征.化疗药物诱导细胞凋亡机制的研究进展[J].福建医药杂志,2007,29(2):95-97. 被引量：3
  • 2Favaretto AG,Pasello G,Magro C.Second and third line treatment in advanced non-small cell lung cancer.Discov Med,2009,8 (43):204-209.
  • 3Fukuoka M,Wu YL,Thongprasert S,et al.Biomarker analyses and final overall survival results from a phase Ⅲ,randomized,openlabel,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).J Clin Oncol,2011,29 (21):2866-2867.
  • 4Shepherd FA,Rodrigues PJ,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer,N Engl J Med,2005,353 (2):123-132.
  • 5Okabe T,Okamoto I,Tsukioka S,et al.Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines:role of gefitinib-induced downregulation of thymidylate synthase.Mol Cancer Ther,2008,7 (3):599-606.
  • 6Van Schaeybroeck S,Kyula J,Kelly DM,et al.Chemotherapyinduced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.Mol Cancer Ther,2006,5 (5):1154-1165.
  • 7Giovannetti E,Lemos C,Tekle C,et al.Molecular mechanisms underlying the synergistic interaction of erlotinib,an epidermal growth factor receptor tyrosine kinase inhibitor,with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.Mol Pharmacol,2008,73 (4):1290-1300.
  • 8Cheng H,An S J,Dong S,Zhang YF,et al.Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant nonsmall cell lung cancer cell lines treated with paclitaxel and gefitinib.J Hematol Oncol,2011,4:5.
  • 9J(a)nne PA,Wang X,Socinski MA,et al.Randomized phase Ⅱ trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced ltng adenocarcinoma:CALGB 30406 trial.J Clin Oncol,2012,30(17):2063-2069.
  • 10Chen P,Wang L,Liu B,et al.EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer:a meta-analysis.Eur J Clin Pharmacol,2011,67(3):235-243.

引证文献4

二级引证文献16

中国老年学杂志
2009年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部